TEMPUS Trial Finds No Short-Term Advantage for Time-Restricted Eating or Exercise on Liver Fat
In adults with obesity, an 8-hour time-restricted eating schedule, a supervised exercise program, and the two strategies combined failed to outperform usual care for reducing intrahepatic fat fraction over 12 weeks. The multicenter-style randomized comparison, conducted in Granada, Spain, tested a clinically attractive idea: whether tightening the daily eating window, increasing structured physical activity, or doing both at once could accelerate liver fat loss beyond standard Mediterranean diet and physical activity education.
The answer was no.
That result lands in a field where excess liver fat is tightly linked to insulin resistance, dyslipidemia, and future metabolic disease. A strategy can look biologically elegant and still fail to move the needle over a short interval, especially when the comparator already includes diet and activity counseling. Here, the control arm was not inert placebo care; it reflected a realistic baseline intervention that itself can influence weight, energy balance, and liver fat.
Randomized Comparison Across Four Intervention Arms
The trial enrolled 187 adults with obesity, half of them women, between May 2023 and April 2024. Participants were randomized to usual care alone, time-restricted eating alone, supervised exercise alone, or the combination of both interventions. All 187 participants entered the primary intention-to-treat analysis: usual care included 48 participants, time-restricted eating 46, exercise 47, and the combined arm 46.
The primary endpoint was the change in intrahepatic fat fraction, measured by magnetic resonance imaging after 12 weeks. Blinding was preserved for the primary outcome assessors and statisticians, while intervention personnel necessarily remained unblinded because of the nature of the behavioral treatments. That structure strengthened the credibility of the endpoint assessment even in a trial where adherence and daily behavior could not be masked.
Liver Fat Did Not Fall More With Time-Restricted Eating
Time-restricted eating produced a mean intrahepatic fat fraction change of -0.4%, with a 95% confidence interval from -2.0 to 1.2, and a P value of 0.93 versus usual care. In practical terms, there was no signal that limiting food intake to an 8-hour window delivered an additional liver-fat reduction over the 12-week period. The confidence interval crossed zero comfortably, and the point estimate sat close to no effect.
The finding is important because time-restricted eating has often been promoted as a way to simplify energy restriction without requiring meticulous calorie counting. Yet liver fat is a demanding endpoint. It responds to sustained negative energy balance, improvement in hepatic insulin sensitivity, and reductions in visceral adiposity; a time window alone does not guarantee those conditions will be met, especially if total caloric intake remains similar.
Supervised Exercise Also Missed the Primary Endpoint
The supervised exercise arm showed a mean change of -0.8% in intrahepatic fat fraction, with a 95% confidence interval from -2.4 to 0.8 and a P value of 0.54 versus usual care. Physiologically, exercise remains a sound intervention for cardiometabolic health because it can improve skeletal muscle glucose handling, increase energy expenditure, and reduce ectopic fat over time. Even so, the trial did not show a short-term liver-fat advantage over the education-based comparator.
This is where duration matters in a mechanistic sense. Short-term exercise programs may improve fitness and metabolic flexibility before measurable liver fat changes emerge, and the magnitude of change can be diluted if baseline counseling in the control arm already nudges participants toward better food choices and more activity. A 12-week window can be enough to see some metabolic shifts, but not always enough to separate closely related lifestyle approaches when the endpoint is hepatic fat quantified by MRI.
The Combined Arm Did Not Create Additive Benefit
The most ambitious hypothesis in the trial was that combining dietary timing with supervised training would compound the effect. It did not. The time-restricted eating plus exercise arm produced a mean intrahepatic fat fraction change of -1.1%, with a 95% confidence interval from -2.7 to 0.5 and a P value of 0.28 compared with usual care.
No between-group differences emerged among the three active intervention arms either. The numerical spread across treatments was small, and none of the regimens established superiority over the others. For clinicians, this is a reminder that pairing two plausible interventions does not automatically produce additive hepatic benefit within a short timeframe. Metabolic adaptation, compensation in nonexercise activity, and incomplete adherence can all erode the expected gain from a combined behavioral plan.
What the Negative Primary Outcome Means at the Bedside
The result does not make time-restricted eating or exercise irrelevant. It does mean that, for adults with obesity and the specific goal of reducing intrahepatic fat over 12 weeks, neither strategy proved better than usual care built around Mediterranean diet and physical activity education. The trial was carefully randomized and used imaging-based quantification of liver fat, so this was not a vague symptom report or a surrogate based on self-report.
For bedside decision-making, the most defensible reading is narrower: short-term behavioral interventions may be useful for broader health goals, but they should not be assumed to deliver superior hepatic fat reduction unless the patient achieves meaningful, sustained changes in energy balance and metabolic burden. Liver fat is often more resistant to quick fixes than public messaging suggests.
The study’s timing also deserves attention. A 12-week endpoint is clinically relevant for behavior change, yet hepatic fat remodeling may require longer exposure to distinguish one lifestyle strategy from another. The absence of benefit in this window leaves open whether a longer program, stronger dietary prescription, different exercise dose, or a more intensively supported adherence model would produce a different result.
Why These Data Matter for Obesity-Related Liver Disease
Intrahepatic fat fraction is not just a laboratory curiosity. It tracks with the metabolic stress that drives steatotic liver disease and often serves as an early marker of whether an intervention is meaningfully changing hepatic substrate handling. In this trial, the failure of all three active strategies to outperform usual care suggests that the control condition was already potent enough to narrow differences, or that the interventions themselves were insufficiently intense over 12 weeks to shift liver fat further.
The trial was registered as NCT05897073 and completed on 5 September 2025. Its findings place a brake on overly confident claims that an 8-hour eating window, supervised exercise, or their combination will rapidly reduce liver fat in obesity. Any future study will need to address adherence, treatment dose, and longer follow-up before assuming that the path from behavioral enthusiasm to hepatic benefit is straightforward.